Linezolid is best used for:
## **Core Concept**
Linezolid is an antibiotic used to treat various bacterial infections. It belongs to the class of **oxazolidinones**, which work by inhibiting protein synthesis in bacteria. This mechanism is crucial for understanding its use in clinical practice.
## **Why the Correct Answer is Right**
The correct answer, **D. Infections caused by MRSA (Methicillin-resistant Staphylococcus aureus) and Vancomycin-resistant Enterococci (VRE)**, is right because linezolid is particularly effective against Gram-positive bacteria, including MRSA and VRE. These pathogens are often resistant to multiple antibiotics, making linezolid a valuable treatment option. Linezolid's mechanism of action involves binding to the 50S ribosomal subunit of bacteria, which inhibits the initiation phase of protein synthesis. This unique mechanism allows it to be effective against bacteria that are resistant to other antibiotics.
## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because linezolid is not specifically indicated for infections caused by Gram-negative bacteria. Its spectrum of activity is mainly limited to Gram-positive bacteria.
- **Option B:** This option is incorrect as linezolid is not the first choice for treating tuberculosis. Drugs like isoniazid, rifampicin, pyrazinamide, and ethambutol are standard for TB treatment.
- **Option C:** This option is incorrect because linezolid is not primarily used for anaerobic infections. While it may have some activity against certain anaerobic bacteria, it is not the drug of choice for anaerobic infections, which are often treated with drugs like metronidazole or clindamycin.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that linezolid can cause **myelosuppression** as a side effect, which may lead to thrombocytopenia, anemia, and leukopenia. This adverse effect is dose- and duration-dependent, making it essential to monitor patients on long-term therapy.
## **Correct Answer: D. Infections caused by MRSA and Vancomycin-resistant Enterococci.**